SOMATIX ADDS NEUROSCIENTIST
SOMATIX ADDS NEUROSCIENTIST ALAMEDA, Calif., Aug. 31 /PRNewswire/ -- Somatix Therapy Corp.
(NASDAQ: SOMA) today announced the appointment of Ronald J. Mandel, Ph.D. as section head for in vivo models in the company's neural diseases program. Previously an assistant professor at the University of Illinois, Mandel will have responsibility for developing small animal models. Mandel, who earned his Ph.D. from the University of Southern California and completed post-doctoral training at the University of California, San Diego, School of Medicine and University of Lund, Sweden, has focused his research on developing appropriate rodent models of Parkinson's, Alzheimer's and Huntington's diseases as well as exploring neural transplantation as a treatment strategy.
According to David Carter, chief executive officer, "Ron is a superb scientist. He has expertise in the neural diseases that Somatix is targeting for gene therapy treatments. He also has the quantitative skills required to accurately analyze and assess the success of our neural models." Somatix Therapy Corp. is a leader in the field of gene therapy. The company is focused on the genetic modification of selected human cells to enable the production and delivery of therapeutic substances within the patient's body. Somatix believes that gene therapy, which requires gene transfer technology, will provide a safe and effective means of delivering many therapeutic substances. Somatix has gene therapy programs in cancer, neural diseases and blood disorders. -0- 8/31/92 /CONTACT: Julie Wood of Somatix Therapy, 510-748-3082/ (SOMA) CO: Somatix ST: California IN: MTC SU: PER
RM -- SF006 -- 4967 08/31/92 12:32 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 31, 1992|
|Previous Article:||FLORIDA KEYS ELECTRIC COOPERATIVE ASSOCIATION ISSUES UPDATED REPORT|
|Next Article:||TAXPAYERS MAY DECLARE CASUALTY LOSSES ON THEIR 1991 RETURNS; IRS ANNOUNCES DEADLINE EXTENSIONS; EXAMINATIONS AND COLLECTIONS SUSPENDED|